特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場アクセスにおける課題:HIV (EU5カ国)

Market Access Impact: HIV (EU5) 2018

発行 FirstWord 商品コード 497069
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
市場アクセスにおける課題:HIV (EU5カ国) Market Access Impact: HIV (EU5) 2018
出版日: 2018年03月01日 ページ情報: 英文
概要

当レポートでは、EU5カ国 (フランス・イタリア・ドイツ・スペイン・英国) の感染症専門医150名を対象にHIV治療薬の処方動向を調査し、市場アクセスにおける各種障壁と処方への影響、主要9ブランド薬の処方に関する比較分析・個別分析を行っています。

調査課題

  • 各種障壁の市場アクセスへの影響
    • 医師がもっとも多く処方するブランドは?
    • 市場の障壁は処方の意思決定にどのように影響しているか?
    • 各種障壁に影響力の違いはあるか?
  • 各ブランドへの障壁の影響
    • 各ブランドを処方する医師の数は?処方していないが検討するつもりの数は?
    • 処方しない理由は?その代わりに処方しているものは?
    • 市場シェアを取り合っている競合ブランドは?

調査対象

  • Descovy (エムトリシタビン/テノホビルアラフェナミド:Gilead)
  • Genvoya (コビシスタット/エルビテグラビル/エムトリシタビン/テノホビルアラフェナミド:Gilead)
  • Isentress (ラルテグラビル:Merck Sharp & Dohme)
  • Prezista (ダルナビル:Janssen Cilag)
  • Reyataz (アタザナビル:BMS)
  • Stribild (コビシスタット/エルビテグラビル/エムトリシタビン/テノホビルジソプロキシルフマル酸塩:Gilead)
  • Triumeq (アバカビル/ドルテグラビル/ラミブジン:ViiV Healthcare)
  • Truvada (エムトリシタビン/テノホビルジソプロキシルフマル酸塩:Gilead)
  • Viread (テノホビルジソプロキシルフマル酸塩:Gilead)
目次

Market barriers affect just over a tenth of HIV prescriptions. Is your brand losing out?

In EU5 markets, where market barriers affect just over one in 10 HIV prescriptions, no single brand has a significant lead over other brands. Market share for all players is up for grabs! Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: HIV (EU5) [2018].

Based on a survey of 150 infectious disease specialists from the EU5 markets (France, Germany, Italy, Spain, UK), the report covers 11 major therapies from Gilead, ViiV, Merck Sharp & Dohme, BMS and Janssen Cilag. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect just over one in 10 prescriptions: But is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Seven brands gain share due to barriers: But no single brand has a significant lead. Could this mean market share is up for grabs? How could you exploit this and gain share for your brand?
  • Two brands see a significant loss: These brands lose over 1% market share because of barriers. Why? And can this be prevented?Eliminating barriers would have the most impact at the bottom of the table: Removing barriers wouldn't change the top of the table, but brands in the lower half of the table could benefit. Is your brand in a position to gain market share?
  • Two brands have a perception problem: Between 20-23% of surveyed doctors would not prescribe these brands, leaving other brands to capture market share.

Insight into 11 Major HIV Drugs

  • Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Tivicay (dolutegravir; ViiV Healthcare)
  • Isentress (raltegravir; Merck Sharp & Dohme)
  • Edurant (rilpivirine; Janssen Cilag)
  • Prezista (darunavir; Janssen Cilag)
  • Reyataz (atazanavir; Bristol-Myers Squibb)
  • Rezolsta (darunavir/cobicistat; Janssen Cilag)

Exploring Market Access Barriers

Market Access Impact: HIV (EU5) explores key issues affecting HIV drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 infectious disease specialists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between March 5-12, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary